Leerink Partners Adjusts Earnings Estimate for Inspire Medical Systems (INSP) FY2028

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) has recently come under the scrutiny of analysts from Leerink Partners, who have revised their earnings per share (EPS) estimates for the company for the fiscal year 2028. In a report dated Tuesday, February 11th, analyst M. Kratky from Leerink Partners updated the expected EPS figure to $5.62, slightly down from a previous estimate of $5.69. This reduction comes in light of varying market conditions and company performance metrics as observed in the recent earnings reports.

The consensus EPS estimate for Inspire Medical Systems for the current fiscal year is considerably lower, standing at $1.33. This presents an interesting comparison and highlights the anticipated growth trajectory for the company over the next few years.

Additionally, several other investment research firms have recently shared their analyses concerning INSP stock. Morgan Stanley adjusted their target price for shares of Inspire Medical Systems from $230.00 to $220.00 but maintained an "overweight" rating. Meanwhile, Truist Financial has also lowered their price target for the stock from $250.00 to $235.00, while keeping a "buy" rating intact. In a broader show of support, Bank of America upgraded Inspire Medical Systems from a "neutral" rating to a "buy" rating and increased their price objective from $220.00 to $255.00.

Another significant adjustment came from Robert W. Baird, who reduced their target price from $252.00 to $248.00, while still rating the stock as "outperform." KeyCorp reaffirmed an "overweight" rating and slightly decreased their price target to $234.00 from $236.00. Collectively, among analysts covering the stock, there are three hold ratings and eight buy ratings, suggesting a strong favorable outlook. Based on data from MarketBeat.com, the average rating for Inspire Medical Systems' stock is categorized as a "Moderate Buy" with a consensus price target of $228.82.

As for the stock's performance, shares of INSP opened at $183.17 on Wednesday, reflecting a modest increase in value. The company's 50-day moving average price is noted at $189.39, while the 200-day moving average price stands at $191.39. It’s noteworthy that Inspire Medical Systems has experienced a 52-week low of $123.00 alongside a high of $257.40, indicating a significant fluctuation in its market valuation.

Inspire Medical Systems most recently reported its quarterly earnings on February 10th, where it delivered an EPS of $1.15. This result was notably above the consensus estimate of $0.74, demonstrating strong operational capabilities with a return on equity of 5.30% and a net margin of 4.37%.

Institutional Investor Trends

Recent changes in institutional holdings reflect growing confidence in Inspire Medical Systems. WINTON GROUP Ltd boosted its stake by 15.6% in the fourth quarter, now owning 5,977 shares valued at approximately $1,108,000. Similarly, Vanguard Group Inc. increased its holdings by 1.2%, accumulating 3,270,357 shares worth around $606 million. Other institutional players, such as KLP Kapitalforvaltning AS and Sei Investments Co., also made moves to enhance their stakes, emphasizing a strong institutional presence behind the company.

In summary, while Leerink Partners has adjusted their FY2028 earnings estimates for Inspire Medical Systems to $5.62, the overall market sentiment remains broadly positive, as indicated by multiple affirmative assessments from other analysts. The company, active in developing solutions for obstructive sleep apnea (OSA), stands poised for potential growth in a market ripe with opportunity.

Earnings, Stocks, Investment